Expression of Pituitary Tumor Transforming Gene 1 is an Independent Factor of Poor Prognosis in Localized or Locally Advanced Prostate Cancer Cases Receiving Hormone Therapy

We investigated the prognostic value of pituitary tumor transforming gene 1 (PTTG1) expression according toclinicopathological features among localized or locally advanced prostate cancer cases receiving hormone therapy.A retrospective study involved 64 patients receiving combined androgen blockade treatment was performed.PTTG1 expression was determined by immunohistochemical staining using initial needle biopsy specimensfor diagnosis. Associations of PTTG1 with various clinicopathological features and disease-free survival wereexamined via uni- and multivariate analyses. No association between PTTG1 expression and clinical T stage,Gleason score, pretreatment PSA levels, risk groups was found (p =0.682, 0.184, 0.487, 0.571, respectively).Univariate analysis revealed that increased PTTG1 expression, T3 stage and high risk group were associatedwith increased risk of disease progression (p =0.000, 0.042, and 0.001), and high PSA level had a tendency topredict disease progression (p =0.056). Cox hazard ratio analysis showed that PTTG1 low expression (p =0.002),PTTG1 high expression (p =0.000) and high risk group (p =0.0147) were significantly related to decreased diseasefreesurvival. In conclusion, PTTG1 expression determined by immunohistochemical staining in needle biopsyspecimens for diagnosis is a negative prognostic factor for progression in localized or locally advanced prostatecancer receiving hormone therapy.